Oncology and Hematology
17-32 of 157
- MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
1.00 program credit
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Kathleen Moore, MD, MS
Joyce F. Liu, MD, MPH
- MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
0.50 program creditsJoyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
- MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
0.50 program creditsJoyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
Joyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Lauren A. Byers, MD
- MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program creditsLuis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
